CAMXCamurus AB (publ)
624.50SEK-0.87%Mkt Cap: 3.55B $P/E: 55.36

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphi…

Key Statistics

Company
Market Cap3.55B $
Enterprise Value3.21B $
Revenue (TTM)216.82M $
Gross Profit201.75M $
Net Income (TTM)70.36M $
Revenue/Share3.636 USD
Last Price624.50 SEK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees316
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN
Valuation
P/E (Trailing)55.36
P/E (Forward)40.45
PEG
EV/EBITDA40.74
EV/Revenue14.79
P/S16.34
P/B7.92
EPS (TTM)11.29
EPS (Forward)15.39
52W Range
430.8060% of range754.50
52W High754.50 SEK
52W Low430.80 SEK
Profitability
Gross Margin93.11%
Oper. Margin41.66%
EBITDA Margin36.31%
Profit Margin32.47%
ROE17.37%
ROA15.52%
Growth
Revenue Growth3.90%
Earnings Growth-1.50%
Cash Flow & Leverage
Operating CF83.15M $
CapEx (TTM)13.25M $
FCF Margin17.87%
FCF Yield1.09%
Net Debt-378.80M $
Net Debt/EBITDA-4.81
Balance Sheet
Debt/Equity0.03
Current Ratio10.01
Quick Ratio9.35
Book Value/Sh78.65 SEK
Cash/Share68.37 SEK
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 SEK
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Analyst Consensus
Rating
Target (Mean)793.00 SEK
Upside (mean)+27.0%
Target Range650.00 SEK914.00 SEK
SEK650.00+27.0% to meanSEK914.00
# Analysts8
Ownership
Shares Out.59.51M
Float38.94M
Insiders33.12%
Institutions43.94%
Technical
SMA 50584.12 (+6.9%)
SMA 200570.91 (+9.4%)
Beta0.52
S&P 52W Chg18.16%
Avg Vol (30d)75.67K
Avg Vol (10d)57.08K
Technical Indicators
RSI (14)60.7
MACD10.9861
MACD Signal11.2923
MACD Hist.-0.3062
BB Upper638.57 SEK
BB Middle616.80 SEK
BB Lower595.03 SEK
BB Width7.06%
ATR (14)19.77 SEK
Vol Ratio (20d)0.93x